Compare Akamai Technologies, Inc. (AKAM) vs Revvity Inc (RVTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Akamai Technologies, Inc. vs Revvity Inc — how do they compare? Akamai Technologies, Inc. trades at $124.01 (market cap $16.63B), while Revvity Inc trades at $109.55 (market cap $12.50B). The key difference: Akamai Technologies, Inc. is the larger of the two by market cap, and Revvity Inc pays a 0.25% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| AKAM | RVTY | |
|---|---|---|
Market Cap | $16.63B | $12.50B |
Sector | Technology | Technology |
52-Week High | $161.14 | $117.75 |
52-Week Low | $70.53 | $82.26 |
Enterprise Value | $21.56B | $14.99B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $114.37, up 1.06% on the day but down significantly from its 26-year high of $165.45 in May 2026. The stock faces a bearish technical signal despite recent earnings beats. Revenue growth has slowed to 5% annually, with net income margin declining from 14.47% in 2022 to 10.74% in 2025. The company continues strategic moves in cybersecurity, completing the LayerX acquisition and expanding its NVIDIA partnership for AI security.
While analyst consensus remains positive with a $170.20 price target, near-term headwinds include declining profitability, high valuation multiples, and competitive pressures. The stock's current pullback presents a potential entry point for long-term investors believing in its cybersecurity and cloud computing positioning, though execution risks and margin compression require monitoring.
Revvity (RVTY) trades at $112.95, down 0.71% on the day, with strong technical momentum indicated by bullish moving averages. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent AI integration announcements with Anthropic's Claude platform highlight ongoing innovation in scientific R&D workflows.
The stock presents a mixed outlook with strong earnings performance and AI-driven growth initiatives offset by elevated valuation multiples. Key risks include margin pressure and competitive threats in the life sciences sector. Analyst consensus leans bullish with a $109.38 price target, though current price exceeds this level.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
